JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harold L. Lazar
Yusheng Bao
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazar, H. L.
Right arrow Articles by Bernard, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazar, H. L.
Right arrow Articles by Bernard, S. A.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Molecular biology
Right arrow Myocardial protection

J Thorac Cardiovasc Surg 2003;125:1037-1042
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Pretreatment with statins enhances myocardial protection during coronary revascularization

Harold L. Lazar, MD, Yusheng Bao, MD, Yu Zhang, BS, Sheilah A. Bernard, MD

From the Department of Cardiothoracic Surgery, The Boston Medical Center and The Boston University School of Medicine, Boston, Mass.

Supported in part by a research grant from Pfizer, Inc.

Read at the Eighty-second Annual Meeting of The American Association for Thoracic Surgery, Washington, DC, May 5-8, 2002.

Received for publication May 29, 2002. Revisions requested Aug 16, 2002; revisions received Aug 22, 2002. Accepted for publication Aug 26, 2002. Address for reprints: Harold L. Lazar, MD, Department of Cardiothoracic Surgery, Boston Medical Center, 88 E Newton St, Suite B404, Boston, MA 02118 (E-mail: harold.lazar{at}bmc.org).

Objective: This experimental study was undertaken to determine whether pretreatment with statins would enhance myocardial protection and minimize ischemic injury during revascularization of acutely ischemic myocardium.
Methods: In 20 pigs the second and third diagonal arteries were occluded for 90 minutes, followed by 45 minutes of blood cardioplegic arrest and 180 minutes of reperfusion. Ten pigs received atorvastatin (40 mg orally every day) for 21 days before surgical intervention; 10 others received no statins. Ischemic damage was assessed on the basis of the need for cardioversions for ventricular arrhythmias, regional wall-motion scores (4 = normal to -1 = dyskinesia) were determined by means of 2-dimensional echocardiography, endothelial function was assessed on the basis of bradykinin-induced coronary artery relaxation, and infarct size was calculated by determining the area of necrosis to the area of risk by means of histochemical staining. Results are given as means ± SE.
Results: Statin-treated animals required fewer cardioversions (0.11 ± 0.01 vs 2.87 ± 0.20, P = .0001), had improved wall-motion scores (2.81 ± 0.10 vs 1.52 ± 0.08, P = .01), had lower infarct size (21% ± 2% vs 41% ± 2%, P = .0001), and had more complete coronary artery relaxation (34% ± 5% vs 8% ± 4%, P = .01). Total serum cholesterol levels were similar between the groups (62 ± 5 mg/dL for statin-treated animals vs 68 ± 5 mg/dL for non-statin-treated animals, P = .30).
Conclusions: Pretreatment with statins enhances myocardial protection during revascularization by means of mechanisms that are independent of their cholesterol-lowering properties.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.